Brasco Group Invest 8 Million Euro in Charles Real Estate Joint Venture Deal
22.2.2023 20:34:00 EET | Business Wire | Press release
The Brasco B.V. conglomerate is establishing a joint venture with the real estate company Charles Real Estate.
The Dutch company is thus consolidating its position in the German residential and commercial real estate market.
The Brasco Group continues on its investment tour: with its strategic investment in the joint venture with Charles Real Estate, the Dutch conglomerate is further diversifying its portfolio.
As a first step, the Brasco Group is investing EUR 8 million in the joint venture, and in the course of 2023 is planning to invest a further EUR 30 million.
Charles Real Estate, based in Berlin, has a portfolio of 550 units in Germany with a total lettable space of more than 33,000 square metres. The company's portfolio also includes a property currently under construction with a gross floor area of 16,000 square metres.
Industry insiders regard the investment as proof of the German real estate market's stability. As the coronavirus pandemic appears to have been largely overcome and the energy crisis has been less severe than initially feared, analysts see further growth potential in the German real estate market.
This is already the second investment by the Dutch group to attract attention this year: at the beginning of February, the company announced that it was investing in Mood's Clinic, a well-known manufacturer of medical cannabis.
The Brasco Group is a Dutch conglomerate and parent company of the Brasco group of companies. The Group specialises in trade and logistics, real estate development, financial services – in particular private equity – and the distribution of textiles. The main task of the parent company is to define the strategic orientation of the individual spheres of business and to promote their growth as well as the use of synergies through investment and communication.
The Dutch conglomerate relies on innovative trade concepts to remain competitive in the global and fast-moving circulation of goods and services.
The Group's core competence in the real estate sector is the purchase and management of existing high-end properties in sought-after locations within the Federal Republic of Germany.
The Brasco Group's finance division is responsible for managing and controlling the finances of subsidiaries, suppliers, partners, shareholders and investors. Only employees of the Brasco group of companies are authorised to manage finances, which ensures finances are managed securely.
The investment division of the conglomerate plays a central role in the acquisition of majority stakes: in recent decades, the company has advised on half of all global buyouts with a sales volume of more than $500 million. In addition to buy-out funds, the Brasco Group advises on other types of fund, including hedge funds, real estate funds, private equity funds and infrastructure funds. The Dutch company also advises pension fund, sovereign wealth fund and foundation managers.
More than 1,000 investment experts are associated with the company, and they accompany the investment cycle from the contract negotiation stage to planning the withdrawal.
The Brasco Group intends to float itself on the stock market at the end of 2024.
The Managing Director of the Brasco Group is Rafy Ahmed.
Rafy Ahmed is known to the public from the TV show "Lion's Den". Ahmed founded the fashion brand "Morotai" in 2017 which specialises in sportswear. In 2018, he was awarded the Founder's Prize of the State of Baden-Württemberg. In addition to his work as CEO, he is a lecturer at the International School of Management (ISM) in Stuttgart. As a successful young entrepreneur, he shows students how to start their career. The ISM Stuttgart intends to make the course he teaches an integral part of the "Global Brand & Fashion Management" degree course.
|
Language: |
English |
|
Company: |
Brasco Group |
|
Rivium Boulevard 301 beganegrond en 1e etage |
|
|
2909LK Capelle aan den IJsse |
|
|
Netherlands |
|
|
Internet: |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005788/en/
Contact information
Name: Rafy Ahmed
Tel: +905337840707
Email: info@brascogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom